Forecasted · Cooperative Agreement
Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- RFA-DK-28-116
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close February 10, 2027 (agency estimate)
- Agency estimates
- Estimated posting: December 1, 2026. Estimated award date: November 1, 2027. Estimates can change.
- Published award range
- Not published by the agency
- Estimated total program funding
- $5,000,000
- Expected number of awards
- 1
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.847
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/363678 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 363678 · Funding opportunity number RFA-DK-28-116
- Posted
- August 20, 2026 · Source last updated August 20, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 92% of key fields published by the sourceNot published: published funding range.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description (from the official listing)
Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression. Over the past two decades, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has supported major T1D research consortia covering basic, translational, and clinical research. Each consortium has focused on different aspects of T1D, such as specific organs, stages of disease or clinical outcomes. Together, these consortia have collected large longitudinal and multimodal datasets using standardized protocols and coordinated studies. While individual consortia have improved our understanding of specific areas, combining their work offers a rare opportunity to see how different biological processes interact to drive T1D development and progression. This integrated view can answer fundamental questions about T1D biology that cannot be answered using individual datasets or studies alone. Recent advances in artificial intelligence (AI) now make it possible to integrate these complementary datasets and study T1D across various tissues, disease stages, and biological levels. Building on these resources, NIDDK will support a coordinated, milestone-driven research project to answer fundamental questions about T1D biology and accelerate the development of personalized medicine. The project will combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as T1D develops and…
Read the full description
Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression. Over the past two decades, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has supported major T1D research consortia covering basic, translational, and clinical research. Each consortium has focused on different aspects of T1D, such as specific organs, stages of disease or clinical outcomes. Together, these consortia have collected large longitudinal and multimodal datasets using standardized protocols and coordinated studies. While individual consortia have improved our understanding of specific areas, combining their work offers a rare opportunity to see how different biological processes interact to drive T1D development and progression. This integrated view can answer fundamental questions about T1D biology that cannot be answered using individual datasets or studies alone. Recent advances in artificial intelligence (AI) now make it possible to integrate these complementary datasets and study T1D across various tissues, disease stages, and biological levels. Building on these resources, NIDDK will support a coordinated, milestone-driven research project to answer fundamental questions about T1D biology and accelerate the development of personalized medicine. The project will combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as T1D develops and progresses. The research will generate new insights into T1D biology, help us understand the different forms and stages of T1D, identify biomarkers, and inform new approaches for disease prevention, intervention, and treatment. To support the research, the project will develop and test advanced multimodal AI models. It will also develop AI-enabled research workflows, new methods to integrate data, and privacy-preserving synthetic datasets.
Agency contact
Division of Diabetes, Endocrinology and Metabolic Diseases
NIDDK_DEM@nih.gov